

Attorney Docket No.: RTS-0339
Inventors: Kenneth W. Dobie
Serial No.: 10/024,396
Filing Date: December 18, 2001
Page 2

*SUB
B
A2
A2 content*

said compound specifically hybridizes with said nucleic acid molecule encoding CD36L1 and inhibits the expression of CD36L1.

Please cancel claim 3.

REMARKS

This preliminary amendment is being made in response to a telephone interview with Examiner Schultz on April 9, 2002. Claim 3 has been canceled. Claim 1 has been amended to incorporate the SEQ ID NO. of the target sequence. This amendment to the claim is based on teachings throughout the specification as filed. No new matter has been added by this amendment.

Attached hereto is a marked up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE."

Respectfully submitted,

Jane Massey Licata

Jane Massey Licata
Registration No. 32,257

Date: April 10, 2002
Licata & Tyrrell P.C.
66 Main Street
Marlton, N.J. 08053
856-810-1515

Attorney Docket No.: RTS-0339
Inventors: Kenneth W. Dobie
Serial No.: 10/024,396
Filing Date: December 18, 2001
Page 3

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the claims:

Claim 3 has been canceled.

Claim 1 has been amended as follows:

1. (Amended) A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding CD36L1 (SEQ ID NO:3), wherein said compound specifically hybridizes with said nucleic acid molecule encoding CD36L1 and inhibits the expression of CD36L1.